Journal
FEBS LETTERS
Volume 584, Issue 17, Pages 3800-3811Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.febslet.2010.06.009
Keywords
Alternative Lengthening of Telomeres; ALT activity assay; ALT-associated PML body; Telomeric circle; ALT-positive cancer
Funding
- Cancer Council New South Wales
- Cancer Institute New South Wales
- National Health and Medical Research Council of Australia
Ask authors/readers for more resources
Alternative Lengthening of Telomeres (ALT) activity can be deduced from the presence of telomere length maintenance in the absence of telomerase activity. More convenient assays for ALT utilize phenotypic markers of ALT activity, but only a few of these assays are potentially definitive. Here we assess each of the current ALT assays and their implications for understanding the ALT mechanism. We also review the clinical situations where availability of an ALT activity assay would be advantageous. The prevalence of ALT ranges from 25% to 60% in sarcomas and 5% to 15% in carcinomas. Patients with many of these types of ALT[+] tumors have a poor prognosis. (C) 2010 Federation of European Biochemical Societies. Published by Elsevier B. V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available